Forest Laboratories announced today that the company will discontinue sale of memantine (Namenda) 5-mg and 10-mg tablets effective August 15, 2014, in favor of focusing on sales of its once-daily ...
- Indicated for Treatment of Moderate to Severe Alzheimer's Disease - DUBLIN and EMERYVILLE, Calif., Dec. 24, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT) and Adamas Pharmaceuticals Inc. (NASDAQ: ADMS ...
† Noted adverse events were experienced in ≥5% of either treatment group, and had an incidence more than or equal to twice as great in memantine-treated patients than in placebo-treated patients. AE: ...
Forest and Merz Announce FDA Approval of NAMENDA XR for the Treatment of Moderate to Severe Dementia of the Alzheimer's Type NEW YORK, Jun 21, 2010 (BUSINESS WIRE ...
Actavis and Adamas Pharmaceuticals said today they won FDA approval for Namzaric, in a rare favorable outcome for treatments indicated for Alzheimer’s disease. Namzaric is indicated for the treatment ...
Mylan N.V. (Nasdaq: MYL) today announced the U.S. launch of Memantine Hydrochloride Tablets USP, 5 mg and 10 mg, which is the generic version of Forest's Namenda ® Tablets. Mylan received final ...
Association of anticonvulsant prophylaxis in patients with primary and metastatic brain tumors and 1-year overall survival: A systematic review and meta-analysis. This is an ASCO Meeting Abstract from ...
Steven T. DeKosky and Bengt Winblad led this live discussion on how the addition of memantine to the clinician's toolbox will change the management of Alzheimer's disease. Following its FDA approval ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback